Orgenesis, a Maryland-based biotech focussed on cell and gene therapies (CGTs), has completed its acquisition of Tamir Biotechnology’s assets.
The acquisition, which includes TamirBio’s broad spectrum anti-viral platform, was worth $21 million in stock and cash. The deal grants Orgenesis access to ranpirnase.
The first target for ranpirnase is human papillomavirus (HPV), the worldwide leading cause of genital warts.
Topical ranpirnase was evaluated in phase I/II clinical trials targeting genital warts, which demonstrated a clear clinical effect with a good safety profile.
Orgenesis plans to move this program through a phase IIb trial in the US. In addition, anal dysplasia, a precursor to anal cancer, is driven by the HPV virus and will be prioritized in a new clinical trial.
Ranpirnase has also demonstrated a strong safety and tolerability profile in systemic administration.
Unmet needs in serious antiviral indications will be prioritized based on positive preclinical activity on serious viral infections like cytomegalovirus (CMV), influenza, HIV, and SARS. Orgenesis is prioritizing and planning a number of additional clinical trials in some of these indications.
“Ranpirnase has demonstrated clinical efficacy against HPV and other hard to target viruses based on its unique mechanism of action, killing the virus and modulating the immune system, as evidenced by preclinical activity against some of the world’s most persistent viral threats,” said Vered Caplan, CEO of Orgenesis.
“For this reason, we are aggressively pursuing a number of complementary approaches internally to maximize the potential of ranpirnase.”